Hepatocyte Is a Sole Cell Type Responsible for the Production of Coagulation Factor IX In Vivo
- PMID: 28058178
- PMCID: PMC5196924
- DOI: 10.3727/215517912X639496
Hepatocyte Is a Sole Cell Type Responsible for the Production of Coagulation Factor IX In Vivo
Abstract
Coagulation factor IX (FIX) is synthesized by hepatocytes, and the lack of this protein causes hemophilia B. Liver nonparenchymal cells, including liver sinusoidal endothelial cells (LSECs) and extrahepatic cells in the body, are scarcely shown to have an ability to synthesize and secrete FIX. The present study investigated the existence of cells responsible for synthesizing FIX other than hepatocytes in mice using gene expression analyses and FIX-specific clotting assays. Among the several organs investigated, including liver, lung, spleen, kidney, brain, intestine, and tongue, FIX mRNA expressions were observed only in the liver. From the liver, hepatocytes and LSECs were isolated. FIX mRNA expression and FIX protein secretion were observed exclusively in the hepatocytes. Furthermore, the clotting activity of FIX secreted from the cultured hepatocytes was found to be dependent on the concentration of vitamin K2. These findings indicated that the hepatocyte is the only cell type that biochemically produces functional FIX in vivo. This highlights the importance of hepatocytes or cells that are fully differentiated toward the hepatic lineage for possible application for regenerative medicine and for targeting gene delivery to establish new cell-based treatments for hemophilia B.
Keywords: Factor IX; Hemophilia B; Hepatocyte; Nonparenchymal cell.
Figures





Similar articles
-
Development of iPSC-derived FIX-secreting hepatocyte sheet as a novel treatment tool for hemophilia B treatment.Stem Cell Res Ther. 2025 Feb 23;16(1):88. doi: 10.1186/s13287-025-04195-8. Stem Cell Res Ther. 2025. PMID: 39988667 Free PMC article.
-
Cooperation of liver cells in health and disease.Adv Anat Embryol Cell Biol. 2001;161:III-XIII, 1-151. doi: 10.1007/978-3-642-56553-3. Adv Anat Embryol Cell Biol. 2001. PMID: 11729749 Review.
-
In vitro recovery of FIX clotting activity as a marker of highly functional hepatocytes in a hemophilia B iPSC model.Hepatology. 2022 Apr;75(4):866-880. doi: 10.1002/hep.32211. Epub 2021 Dec 12. Hepatology. 2022. PMID: 34687060 Free PMC article.
-
Genetic modification of donor hepatocytes improves therapeutic efficacy for hemophilia B in mice.Cell Transplant. 2010;19(9):1169-80. doi: 10.3727/096368910X503398. Epub 2010 Apr 21. Cell Transplant. 2010. PMID: 20412633
-
Hemophilia Gene Therapy: Ready for Prime Time?Hum Gene Ther. 2017 Nov;28(11):1013-1023. doi: 10.1089/hum.2017.116. Epub 2017 Aug 3. Hum Gene Ther. 2017. PMID: 28793786 Review.
Cited by
-
Nanorobotic artificial blood components and its therapeutic applications: A minireview.Ir J Med Sci. 2024 Jun;193(3):1641-1650. doi: 10.1007/s11845-024-03617-5. Epub 2024 Jan 29. Ir J Med Sci. 2024. PMID: 38282113 Review.
-
A Comparison of Focused and Unfocused Ultrasound for Microbubble-Mediated Gene Delivery.Ultrasound Med Biol. 2021 Jul;47(7):1785-1800. doi: 10.1016/j.ultrasmedbio.2021.02.016. Epub 2021 Mar 31. Ultrasound Med Biol. 2021. PMID: 33812691 Free PMC article.
-
Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy.Blood. 2020 Nov 26;136(22):2524-2534. doi: 10.1182/blood.2020005683. Blood. 2020. PMID: 32915950 Free PMC article. Clinical Trial.
-
Blood Coagulation Factor IX: Structure, Function, and Regulation.IUBMB Life. 2025 May;77(5):e70024. doi: 10.1002/iub.70024. IUBMB Life. 2025. PMID: 40402203 Free PMC article. Review.
-
Production and control of coagulation proteins for factor X activation in human endothelial cells and fibroblasts.Sci Rep. 2020 Feb 6;10(1):2005. doi: 10.1038/s41598-020-59058-4. Sci Rep. 2020. PMID: 32029851 Free PMC article.
References
-
- Birraux J.; Menzel O.; Wildhaber B.; Jond C.; Nguyen T. H.; Chardot C. A step toward liver gene therapy: Efficient correction of the genetic defect of hepatocytes isolated from a patient with Crigler-Najjar syndrome type 1 with lentiviral vectors. Transplantation 87:1006–1012;2009. - PubMed
-
- Bolton-Maggs P. H.; Pasi K. J. Haemophilias A and B. Lancet 361:1801– 1809; 2003. - PubMed
-
- Boost K. A.; Auth M. K.; Woitaschek D.; Kim H. S.; Hilgard P.; Nadalin S.; Blaheta R. A. Long-term production of major coagulation factors and inhibitors by primary human hepatocytes in vitro: Perspectives for clinical application. Liver Int. 27:832–844;2007. - PubMed
-
- Coutu D. L.; Cuerquis J.; El Ayoubi R.; Forner K. A.; Roy R.; Francois M.; Griffith M.; Lillicrap D.; Yousefi A. M.; Blostein M. D.; Galipeau J. Hierarchical scaffold design for mesenchymal stem cell-based gene therapy of hemophilia B. Biomaterials 32:295–305;2011. - PubMed
LinkOut - more resources
Full Text Sources